Sue Cheng

468 total citations
12 papers, 224 citations indexed

About

Sue Cheng is a scholar working on Rheumatology, Ophthalmology and Immunology. According to data from OpenAlex, Sue Cheng has authored 12 papers receiving a total of 224 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Rheumatology, 5 papers in Ophthalmology and 4 papers in Immunology. Recurrent topics in Sue Cheng's work include Otitis Media and Relapsing Polychondritis (5 papers), Ocular Diseases and Behçet’s Syndrome (5 papers) and Psoriasis: Treatment and Pathogenesis (4 papers). Sue Cheng is often cited by papers focused on Otitis Media and Relapsing Polychondritis (5 papers), Ocular Diseases and Behçet’s Syndrome (5 papers) and Psoriasis: Treatment and Pathogenesis (4 papers). Sue Cheng collaborates with scholars based in United States, Türkiye and France. Sue Cheng's co-authors include Maria Paris, Shannon McCue, Gülen Hatemi, Mindy Chen, Mitsuhiro Takeno, Alfred Mahr, Yusuf Yazıcı, Melike Melikoğlu, Do Young ‍Kim and Yoshiaki Ishigatsubo and has published in prestigious journals such as New England Journal of Medicine, Annals of the Rheumatic Diseases and Journal of the American Academy of Dermatology.

In The Last Decade

Sue Cheng

11 papers receiving 220 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sue Cheng United States	7	101	89	57	56	29	12	224
Zheng Tang China	10	42 0.4×	5 0.1×	109 1.9×	57 1.0×	33 1.1×	25	288
Kiyomi Koike Japan	8	10 0.1×	11 0.1×	49 0.9×	13 0.2×	11 0.4×	27	225
Łukasz Kasper Poland	9	29 0.3×	4 0.0×	114 2.0×	18 0.3×	3 0.1×	17	248
S. von Schmiedeberg Germany	9	65 0.6×	3 0.0×	28 0.5×	43 0.8×	14 0.5×	15	271
Shangwen Sun China	7	22 0.2×	3 0.0×	17 0.3×	107 1.9×	29 1.0×	7	270
Silvia Pérez Spain	8	40 0.4×	2 0.0×	11 0.2×	46 0.8×	14 0.5×	17	141
K Yamada Japan	7	56 0.6×	2 0.0×	14 0.2×	47 0.8×	45 1.6×	14	248
Dimitrios Zgouras Germany	9	20 0.2×	3 0.0×	35 0.6×	17 0.3×	45 1.6×	12	311
Grunde Wibetoe Norway	8	241 2.4×	2 0.0×	17 0.3×	88 1.6×	54 1.9×	17	357
Joseph J. Moellman United States	11	178 1.8×	1 0.0×	28 0.5×	103 1.8×	93 3.2×	19	438

Countries citing papers authored by Sue Cheng

Since Specialization

Citations

This map shows the geographic impact of Sue Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sue Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sue Cheng more than expected).

Fields of papers citing papers by Sue Cheng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sue Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sue Cheng. The network helps show where Sue Cheng may publish in the future.

Co-authorship network of co-authors of Sue Cheng

This figure shows the co-authorship network connecting the top 25 collaborators of Sue Cheng. A scholar is included among the top collaborators of Sue Cheng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sue Cheng. Sue Cheng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Benatar, Michael, Emma Ciafaloni, James F. Howard, et al.. (2025). A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis. New England Journal of Medicine. 392(23). 2309–2320. 6 indexed citations

Langley, Richard G., Nehal N. Mehta, Jeffrey Crowley, et al.. (2023). 43250 Efficacy of Apremilast in Patients With Moderate-to-Severe Plaque Psoriasis Across Weight and BMI Subgroups: Analysis From ESTEEM 1 and ESTEEM 2. Journal of the American Academy of Dermatology. 89(3). AB158–AB158. 3 indexed citations

Merola, Joseph F., Lawrence Charles Parish, Lyn Guenther, et al.. (2023). Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trial. Journal of the American Academy of Dermatology. 90(3). 485–493. 13 indexed citations

Mease, Philip J., Gülen Hatemi, Maria Paris, et al.. (2023). Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet’s Syndrome. American Journal of Clinical Dermatology. 24(5). 809–820. 25 indexed citations

Gold, Linda Stein, Kim Papp, David M. Pariser, et al.. (2022). Efficacy and safety of apremilast in patients with mild-to-moderate psoriasis up to 32 weeks: Results from the extension phase of the randomized, phase 3 ADVANCE trial. Journal of the American Academy of Dermatology. 88(2). 430–433.

Hatemi, Gülen, Alfred Mahr, Mitsuhiro Takeno, et al.. (2022). Impact of apremilast on quality of life in Behçet’s syndrome: analysis of the phase 3 RELIEF study. RMD Open. 8(2). e002235–e002235. 8 indexed citations

Taylor, Peter C., Désirée van der Heijde, Robert Landewé, et al.. (2021). A Phase III Randomized Study of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Active Ankylosing Spondylitis. The Journal of Rheumatology. 48(8). 1259–1267. 11 indexed citations

Hatemi, Gülen, Alfred Mahr, Mitsuhiro Takeno, et al.. (2021). Apremilast for oral ulcers associated with active Behçet's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial. Clinical and Experimental Rheumatology. 39(5). 80–87. 17 indexed citations

Hatemi, Gülen, Alfred Mahr, Mitsuhiro Takeno, et al.. (2021). Apremilast for oral ulcers associated with active Behçet's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial.. Clinical and Experimental Rheumatology. 39 Suppl 132(5). 80–87. 5 indexed citations

10.

Hatemi, Gülen, Alfred Mahr, Mitsuhiro Takeno, et al.. (2019). OP0146 EFFICACY OF APREMILAST FOR ORAL ULCERS ASSOCIATED WITH ACTIVE BEHÇET'S SYNDROME OVER 64 WEEKS: RESULTS FROM A PHASE III STUDY. Annals of the Rheumatic Diseases. 78. 148–149. 2 indexed citations

11.

Hatemi, Gülen, Alfred Mahr, Yoshiaki Ishigatsubo, et al.. (2019). Trial of Apremilast for Oral Ulcers in Behçet’s Syndrome. New England Journal of Medicine. 381(20). 1918–1928. 122 indexed citations

12.

Hurbin, Fabrice, Xavier Boulenc, Nikki Daskalakis, et al.. (2011). Clopidogrel Pharmacodynamics and Pharmacokinetics in the Fed and Fasted State: A Randomized Crossover Study of Healthy Men. The Journal of Clinical Pharmacology. 52(10). 1506–1515. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact